Acute myeloid leukemia
Menin inhibitors, FLT3 and IDH combinations, venetoclax backbones and what comes after.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 20 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for acute myeloid leukemia on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 17 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | genetic literature | Clinical | Pathways | Literature | Animal models |
|---|---|---|---|---|---|---|---|---|
| DNMT3A DNA methyltransferase 3 alpha | 0.87 | 0.85 | 0.85 | |||||
| CEBPA CCAAT enhancer binding protein alpha | 0.85 | 0.87 | 0.89 | |||||
| FLT3Peds RMTL fms related receptor tyrosine kinase 3 | 0.85 | 0.55 | 0.87 | |||||
| IDH1Peds RMTL isocitrate dehydrogenase (NADP(+)) 1 | 0.80 | 0.56 | 0.80 | |||||
| TET2Peds RMTL tet methylcytosine dioxygenase 2 | 0.79 | 0.78 | 0.87 | |||||
| SRSF2 serine and arginine rich splicing factor 2 | 0.79 | 0.95 | 0.83 | |||||
| RUNX1 RUNX family transcription factor 1 | 0.78 | 0.87 | 0.85 | |||||
| KITPeds RMTL KIT proto-oncogene, receptor tyrosine kinase | 0.77 | 0.32 | 0.66 | |||||
| ASXL1 ASXL transcriptional regulator 1 | 0.77 | 0.75 | 0.87 | |||||
| GATA2 GATA binding protein 2 | 0.76 | 0.83 | 0.82 | |||||
| KRAS KRas proto-oncogene, GTPase | 0.75 | 0.80 | 0.81 | |||||
| NRAS NRAS proto-oncogene, GTPase | 0.75 | – | 0.87 | |||||
| IDH2Peds RMTL isocitrate dehydrogenase (NADP(+)) 2 | 0.75 | 0.32 | 0.87 | |||||
| TP53Peds RMTL tumor protein p53 | 0.74 | 0.68 | 0.83 | |||||
| JAK2Peds RMTL Janus kinase 2 | 0.73 | 0.74 | 0.79 | |||||
| DDX41 DEAD-box helicase 41 | 0.72 | 0.93 | – | |||||
| TERTPeds RMTL telomerase reverse transcriptase | 0.71 | 0.79 | 0.46 | |||||
| NPM1 nucleophosmin 1 | 0.70 | 0.02 | 0.86 | |||||
| GATA1 GATA binding protein 1 | 0.69 | – | 0.81 | |||||
| PTPN11Peds RMTL protein tyrosine phosphatase non-receptor type 11 | 0.69 | – | 0.82 | |||||
| RARA retinoic acid receptor alpha | 0.69 | – | 0.61 | |||||
| PDGFRBPeds RMTL platelet derived growth factor receptor beta | 0.69 | – | 0.57 | |||||
| SETBP1 SET binding protein 1 | 0.67 | 0.69 | 0.65 | |||||
| PDGFRAPeds RMTL platelet derived growth factor receptor alpha | 0.66 | – | 0.53 | |||||
| NSD1 nuclear receptor binding SET domain protein 1 | 0.66 | 0.83 | 0.36 | |||||
| POLD1 DNA polymerase delta 1, catalytic subunit | 0.66 | – | 0.46 | |||||
| POLE DNA polymerase epsilon, catalytic subunit | 0.66 | – | 0.46 | |||||
| WT1Peds RMTL WT1 transcription factor | 0.65 | 0.24 | 0.79 | |||||
| FANCD2 FA complementation group D2 | 0.64 | – | 0.53 | |||||
| KDR kinase insert domain receptor | 0.64 | – | 0.46 | |||||
| U2AF1 U2 small nuclear RNA auxiliary factor 1 | 0.64 | – | 0.83 | |||||
| ETV6 ETS variant transcription factor 6 | 0.64 | 0.19 | 0.68 | |||||
| RETPeds RMTL ret proto-oncogene | 0.63 | – | 0.46 | |||||
| DNMT1 DNA methyltransferase 1 | 0.62 | – | – | |||||
| SMOPeds RMTL smoothened, frizzled class receptor | 0.62 | – | 0.46 | |||||
| CD33Peds RMTL CD33 molecule | 0.61 | – | – | |||||
| TOP2A DNA topoisomerase II alpha | 0.61 | – | – | |||||
| RARG retinoic acid receptor gamma | 0.61 | – | – | |||||
| PRKCB protein kinase C beta | 0.60 | – | 0.30 | |||||
| PRKD1 protein kinase D1 | 0.60 | – | 0.30 | |||||
| RAD21 RAD21 cohesin complex component | 0.60 | – | 0.72 | |||||
| AXLPeds RMTL AXL receptor tyrosine kinase | 0.60 | – | – | |||||
| EZH2Peds RMTL enhancer of zeste 2 polycomb repressive complex 2 subunit | 0.60 | – | 0.77 | |||||
| RARB retinoic acid receptor beta | 0.60 | – | – | |||||
| TXNRD1 thioredoxin reductase 1 | 0.60 | – | – | |||||
| SBDS SBDS ribosome maturation factor | 0.60 | – | 0.46 | |||||
| PRIM2 DNA primase subunit 2 | 0.59 | – | – | |||||
| POLA2 DNA polymerase alpha 2, accessory subunit | 0.59 | – | – | |||||
| POLD2 DNA polymerase delta 2, accessory subunit | 0.59 | – | – | |||||
| POLD3 DNA polymerase delta 3, accessory subunit | 0.59 | – | – |
33 biomarkers in Acute myeloid leukemia have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Acute Myeloid Leukemia”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 272 accepted items exist; the first 100 were read. This is the published evidence, not treatment advice.
- FLT3 ITD level A
- NPM1 EXON 11 MUTATION level A
- BCR::ABL1 Fusion level A
- FLT3 Mutation level A
- RUNX1::RUNX1T1 Fusion level A
- FLT3 ITD OR FLT3 D835 OR FLT3 I836 level A
- IDH1 Mutation level A
- IDH2 Mutation level A
- KMT2A::v Fusion level A
- DNMT3A R882 level B
- CEBPA Mutation level B
- DEK::NUP214 Fusion level B